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Skin autofluorescence assessment of
cardiovascular risk in people with severe
mental illness
Daniëlle Emmerink, Sybiel Bakker, Thomas Van Bemmel, Eric O. Noorthoorn and Paul Naarding
Background
People with severemental illness (SMI) show significantly shorter
life expectancy, mostly due to more prevalent cardiovascular
disease. Although age is a prominent contributor to contem-
porary risk assessment and SMI usually affects younger people,
these assessments still do not reveal the actual risk. By assessing
advanced glycation end products (AGEs), cardiovascular risk can
be assessed independent of age.
Aims
To establish whether detection of AGEs with the AGE-reader will
give a more accurate cardiovascular risk assessment in people
with SMI.
Method
We compared assessment with the AGE-reader with that of the
Systematic Coronary Risk Evaluation (SCORE) table in a group of
120 patients with SMI.
Results
The AGE-reader showed an increased cardiovascular risk more
often than the SCORE table, especially in the youngest group.
Conclusions
Because of its ease of use and substantiation by studies done on
other chronic diseases, we advocate use of the AGE-reader in
daily care for patients with SMI to detect cardiovascular risk as
early as possible. However, the findings of the current study
should be evaluated with caution and should be seen as pre-
liminary findings that require confirmation by a prospective lon-
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Severe or serious mental illnesses (SMI) are those mental illnesses
that show significant mental signs and symptoms for a long(er)
period and that lead to significant functional limitations and disabil-
ity. The prevalence of SMI in theDutch population is about 1%.Most
people with an SMI have schizophrenia or other psychotic disorders,
mood (including bipolar) disorders or personality disorders.1 The
life expectancy of people with SMI is estimated to be 13–30 years
shorter compared with the general population.2 About 60% of the
total deaths among people with SMI are due to natural causes,
with cardiovascular disease the most frequent cause of premature
death.3 The INTERHEART study showed that abnormal lipids,
smoking, hypertension, diabetes, abdominal obesity, the presence
of psychosocial factors, the lack of consumption of fruit and vegeta-
bles, alcohol consumption and the lack of regular physical activity
account for more than 90% of the population with attributable risk
of an initial acute myocardial infarction.4 The incidence of all of
these risk factors is higher in people with SMI.
Early detection and treatment of these risk factors can therefore
result in significant health benefits, especially in people with a high
primary cardiovascular risk, for example those with SMI. In the
Netherlands, as in many high-income countries, guidelines are
available for general practitioners (GPs) to identify people at high
risk: the Dutch Nederlands Huisartsen Instituut (NHG) Guideline
Cardiovascular Risk Management (CVRM). The risk profile is pri-
marily based on an assessment of traditional risk factors such as
blood pressure, lipids, smoking habits, blood glucose levels and a
family history of cardiovascular disease. The internationally
accepted Systematic Coronary Risk Evaluation (SCORE) table is
part of this guideline. It indicates the 10-year risk of death from car-
diovascular disease and serves as a tool for GPs to determine
whether or not treatment is necessary.5
An alternative method for assessing cardiovascular risk is to
measure the amount of advanced glycation end products (AGEs)
in the skin. Formation of AGEs occurs in all tissues and body
fluids and is part of healthy aging, but they also play a pivotal role
in the development of chronic age-related diseases such as diabetes,
renal failure and cardiovascular disease.6 Many AGEs have charac-
teristic tissue autofluorescence. The AGE-reader (DiagnOptics BV,
Groningen, the Netherlands) is able to measure this tissue fluores-
cence in a fast, easy and non-invasive way.7
Several clinical studies demonstrate that skin tissue autofluor-
escence is a strong and independent risk predictor for mortality,
diabetic complications and cardiovascular events.8–12 Some
earlier studies have investigated skin tissue autofluorescence in
people with psychiatric disorders; those with schizophrenia were
found to have higher levels of AGEs, and it was suggested that
the increased level of oxidative stress in this group gives rise to
these higher levels.13,14 Higher levels of skin tissue autofluores-
cence have also been associated with depressive disorders;
higher levels of AGEs were independently associated with the
severity of depression as well as with diagnosis of depression in
a group of older people with depression.15 In both studies,
emphasis was placed on the aetiological role of AGEs in the devel-
opment of psychopathology. We are interested in the specific
somatic needs of people with SMI, especially with respect to car-
diovascular risk. Because people with SMI frequently experience
their illness and its related behaviour at a younger age, and since
cardiovascular risk estimation by SCORE is largely driven by
age, we assume that the real cardiovascular risk has been underes-
timated. We hypothesised that the cardiovascular risk of patients
with SMI can be estimated more accurately by using the AGE-
reader.
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Participants were all in-patients in long-stay wards of GGNet, a
mental health institute in the Netherlands. They were recruited
between April and June 2015, and all were 18 years or older and
met the criteria as stated in the Dutch consensus on the definition
of patients with an SMI.1. This means that there is a long-lasting
and persisting psychiatric disorder with persistent symptoms and
signs, with a considerable impact on daily functioning (Global
Assessment of Functioning score of less than 70) and with an endur-
ing need for professional help. Eligible participants were informed
about this research through an information letter and permission
was requested for the principal investigator to approach them. If
they agreed, the principal investigator approached the participant,
checked for exclusion criteria and asked for informed consent.
Exclusion criteria were a history of cardiovascular disease, diabetes
and renal failure (serum creatinine >180 or estimated glomerular fil-
tration rate of <40 mL/min) because, by definition, these character-
istics would lead to a high cardiovascular risk and the SCORE would
not be suitable. This study was limited to participants with white
skin because dark skin has been known to influence skin tissue auto-
fluorescence assessment due to light absorption.6 People with a large
number of skin defects on their forearms were also excluded because
this complicates skin autofluorescence. Finally, patients were
excluded if they were unable or unwilling to provide their written
consent. Medical ethical approval for the study was provided in
2015 by the ethical board of the University of Twente, Enschede,
the Netherlands.
Procedures
Cardiovascular risk assessment with the SCORE table
The Dutch NHG Guideline CVRM is an evidence-based guideline
from the Dutch College of General Practitioners dated January
2012, and it is currently the gold standard for GPs to determine
increased risk of cardiovascular disease. Within this guideline, the
SCORE table combines data on age, gender, systolic blood pressure,
smoking status and total cholesterol/high-density lipoprotein
(HDL) ratio to estimate the 10-year risk of a severe cardiac
outcome.5 Using the SCORE table, participants can be divided
into three categories, namely low (<10%) intermediate (10–20%)
or high risk (≥20%), based on cardiovascular morbidity or mortality
in the coming 10 years. All in-patients with SMI in our institute
undergo an annual somatic screening in which the above-men-
tioned cardiovascular risk factors are measured. The data from
the last annual somatic screening of all participants were used to
determine the cardiovascular risk with the SCORE table and to clas-
sify them in one of the three risk groups.
Cardiovascular risk assessment with the AGE-reader
The AGE-reader is a desktop box that illuminates 4 cm2 of the skin’s
surface on the forearm while protecting against surrounding light
with an excitation light in the 300–420 nm range. This light activates
the fluorescent constituents of certain AGEs in tissue, which then
begin emitting light of a different wavelength. The emitted light,
with an intensity between 420–600 nm, is detected using a spec-
trometer. Skin tissue autofluorescence is then calculated as the
ratio between the total emission intensity and the total excitation
intensity multiplied by 100. Through the use of calibrated spectro-
meters, the results obtained by different AGE-reader standard units
are similar. When the skin reflectance R is <12%, an additional
reflection measurement is carried out with a white light-emitting
diode to provide a more reliable skin tissue autofluorescence
value. Each AGE-reader standard unit has a unique calibration
file that is stored on the internal flash drive. Reference values are
based on 456 measurements in Caucasian participants without car-
diovascular disease (smokers and non-smokers).16
Three repeated measurements were performed on an area of
pale, healthy skin on the forearm, with the participants in the
sitting position. The mean of three measurements was used for
further analysis. The AGE-reader reveals four categories: normal
risk, slightly increased risk, increased risk or high risk.
Statistical analyses
We conducted a comparative cohort study on the usability, sensitiv-
ity and specificity of the AGE-reader in participants with SMI.
Cardiovascular risk assessed with the SCORE table was compared
with that of that of the AGE-reader.
Because the CVRM identifies three categories (high, medium
and low) and the AGE-reader provides four categories (normal,
slightly increased, increased and high risk), we combined the
slightly increased and increased scores from the AGE-reader into
one category to allow for comparison. Analysis centred on the
degree of similarity of the categories in percentages, but also
included the degree of similarity corrected for prevalence by using
the intraclass correlation. We also conducted a nonparametric
Wilcoxon U-test (dis-)agreement. We compared the basic data,
but also added 15 years to the age categories in the CVRM score
tables, following studies in diabetes and rheumatoid arthritis.
Furthermore, we compared risk using the transformed (+15
years) CVRM SCORE tables in the sample of participants over
the age of 40. Finally, to investigate the association of age to the dif-
ference between CVRM and AGE-reader scores, we performed a
linear regression on age using difference as the outcome.
Results
General characteristics of the study group
We selected 310 participants with SMI in the long-stay wards of our
institute. Of these, 93 refused to participate and 74 were excluded
because of exclusion criteria. Finally, there was no information on
vascular risk factors from a recent annual screening for 23 of the
participants, so the final study group consisted of 120 participants.
Table 1 shows the characteristics of the study participants. As
expected, most participants suffered from F2 psychotic disorders
according to ICD-10 (1992). Many showed F1 psychoactive drug
use and a large number of participants showed F6 personality disor-
ders or F7 mental handicap. F3 mood disorders and F0 organic
mental disorders occurred infrequently. The majority of the partici-
pants were male, smokers and over 40 years of age (mean age 47.8,
s.d. 15.7). Scores on various components of the SCORE table (blood
pressure, total cholesterol/HDL ratio and smoking habits) are given
along with the subsequent risk category on the SCORE table. The
risk score obtained with the AGE-reader is given next to this in
Table 1.
Comparison of risk assessment with the SCORE table
from the NHG Guideline CVRM v. the AGE-reader
Table 2 describes the degree of agreement between the two risk
assessments in several subpopulations. The table shows that the per-
centage of similarity between the risk assessment with the SCORE
table and the AGE-reader is 27%. In 60% of participants, the risk
estimated with the AGE-reader is higher than with the SCORE.
Even if an additional 15 years of age are added to the SCORE
table, as is done for chronic diseases such as diabetes and rheuma-
toid arthritis, the AGE-reader still estimates a higher risk in 45% of
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participants. If this comparison is done in people over 40 only, the
AGE-reader estimated a higher risk in 30% of participants. In line
with this, the difference in results between the AGE-reader and
the SCORE table with increasing age was significantly reduced:
β =−0.534, P < 0.0001. The time taken for measurement with the
AGE-reader was significantly less than that for the SCORE table
(t =−14.7, d.f. = 119, P < 0.001) (data not shown).
Discussion
In this study, we found that the AGE-reader identifies an increased
risk of cardiovascular risk in participants with SMI more often than
the SCORE table. This is even more notable in the younger group of
SMI participants. We conclude that the traditional risk assessment
may not be adequate for the group of SMI patients, especially those
in the younger age groups. The AGE-reader has been substantially
validated in clinical studies, and this preliminary report advocates
the use of the AGE-reader in clinical practice for the disease man-
agement of people with SMI. However, a longitudinal prospective
cohort study is of course necessary to substantiate a predictive
value of the AGE-reader in this group.
Accumulation of AGEs is linked to the pathophysiology of a
variety of diseases including diabetes, renal disease, cardiovascular
diseases and neurodegenerative disorders.8,17–19 The AGE-reader
has been validated against the gold standard for measuring AGEs
(skin biopsies). Skin tissue autofluorescence was shown to be
strongly correlated with tissue accumulation of AGEs.6,9 More
recently, awareness of the possibility of the aetiological role of
AGEs in various kinds of psychopathology has increased. The for-
mation of AGEs is linked to increased oxidative stress. This oxida-
tive stress can be the result from several factors, including repeated
hyperglycaemia, smoking and hypertension, but probably some
psychosis-related factors as well.12,14 Smoking and other unhealthy
lifestyle habits may be rather extreme in the subgroup of institutio-
nalised patients with SMI, thus leading to excessive formation of
AGEs.20
Clinical implications of the study
For everyday clinical practice, the early detection of the cardiovas-
cular risks of institutionalised patients with SMI is of major import-
ance. Many of these patients may be unable to care for themselves
and/or may have an unhealthy lifestyle. Any specialised centre tar-
geting patients with SMI should therefore include an integrated,
somatic program. This program should include prevention (tar-
geted at lifestyle, physical exercise and education), early detection
(with regular routine controls of cardiovascular parameters, e.g.
with the AGE-reader) and treatment (of cardiovascular risk
factors, e.g. hypertension, diabetes and hypercholesterolemia).
Early detection of risk is crucial because the consequences of all of
these risk factors are almost always suffered many years later.
Strengths and limitations
The strength of our study is that we are among the first to analyse
AGEs in a large group of people with SMI and were able to
compare the results with a traditional method of cardiovascular
risk assessment. We have demonstrated that risk assessment with
the AGE-reader is feasible and possible in a group of institutiona-
lised people with SMI.
There are several limitations of this study that need to be
addressed: first, a large number of the patients in our study
refused to participate. They did not differ in age, gender or diagno-
sis, but did possibly differ in regard to disease severity and psych-
osis-related hostility. This could justify the suggestion that we
overlooked a group of people that is even more at risk. In addition
Table 2 Agreement (%) and intraclass correlation between the AGE-reader and the CVRM analysed on source data and correcting by 15 years
AGE-reader finding Totals
Normal Increased High
CVRM finding Source data <10% risk 19 (15.8%) 61 (50.8%) 8 (6.7%) 88
10–20% risk 7 (5.8%) 5 (4.2%) 3 (2.5%) 15
>20% risk 8 (6.7%) 1 (0.8%) 8 (6.7%) 17
Totals 34 67 19 120
+15 years <10% risk 11 (9.2%) 37 (30.8%) 3 (2.5%) 51
10–20% risk 14 (11.7%) 15 (12.5%) 14 (11.7%) 43
>20% risk 9 (7.5%) 15 (12.5%) 2 (1.7%) 26
Totals 34 67 19 120
+15 years in >40 sample <10% risk 4 (4.7%) 12 (14.1%) 2 (2.4%) 18
10–20% risk 14 (16.5%) 15 (17.6%) 14 (16.5%) 43
>20% risk 9 (10.6%) 13 (15.3%) 2 (2.4%) 24
Totals 27 40 18 85




Number of participants 120
Age (mean – s.d.) 47.8 (15.7)
Age (% over 40 years) 70.8%
Gender (% male) 63.7%
Smoking 65%
Diagnoses ICD-10
F0: Organic mental disorder 6.7%
F1: Mental disorder due to psychoactive
substance abuse
30%
F2: Psychotic disorder 66.2%
F3: Mood disorders 15%
F6: Personality disorders 18.3%
F7: Mental handicap 18.3%
F8: Disorders of psychological development 19.2%
F99: Unspecified mental disorder 8.3%
Number of disorders 1.8 (0.9)
Respiratory rate systolic (mean – s.d.) 130.2 (14.7)
Respiratory rate diastolic (mean – s.d.) 80.4 (8.9)









Slightly higher risk 26.7%
Higher risk category 29.2%
Highest risk category 15.8%
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to this, the AGE-reader is not suitable for dark skin; we had to
exclude several people because of this exclusion criterion. This
will generate some problems in clinical practice, especially in
regions in which more people with SMI have dark skin.
Conclusion
The primary reason for the underestimation of cardiovascular risk
in people with SMI is due to the fact that age is a major contributor
to this estimation, and many people with SMI are below the age of
50. Nevertheless, life expectancy is much lower in people with SMI,
and cardiovascular disease is the most frequent cause of premature
death in people with SMI. This study shows that the AGE-reader
identifies an increased risk more often than the SCORE table, espe-
cially in younger people with SMI. Despite evidence of the predictive
value of the AGE-reader investigated in people with no mental dis-
orders, we may expect the findings to have some validity in the
population with SMI investigated in this study. We must keep in
mind that these are merely preliminary findings that require con-
firmation in a prospective cohort study with sufficient follow-up
data. However, using the AGE-reader to assess cardiovascular risk
in people with SMI at a younger age could improve early recognition
of such risks, therefore we would advocate using this method of risk
assessment. An additional benefit is that the AGE-reader allows a
quick and non-invasive assessment of the AGE accumulation in
skin in less than a minute.
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